RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

Titanium complexes supported by imidazo[1,5-*a*]pyridinecontaining pyrrolyl ligand as catalysts for hydroamination and polymerization reactions, and as antitumor reagent

Jinna Liu, Yuhua Cao, Lei Li, Hao Pei, Yanmei Chen, Jinfa Hu, Yaru Qin, Yahong Li,^{*} Wu Li and Wei Liu^{*}

The syntheses, structures, catalytic properties and antitumor activity of three titanium complexes supported by an imidazo[1,5-a]pyridine-containing pyrrolyl ligand are reported.

PC-3 MCF-7 μΜ

RSC Advances

Page 2 of 9

ARTICLE

Cite this: DOI: 10.1039/x0xx00000x

Received ooth January 2012, Accepted ooth January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Titanium complexes supported by imidazo[1,5*a*]pyridine-containing pyrrolyl ligand as catalysts for hydroamination and polymerization reactions, and as antitumor reagent

Jinna Liu,^{*a*} Yuhua Cao,^{*b*} Lei Li,^{*a*} Hao Pei,^{*a*} Yanmei Chen,^{*a,c*} Jinfa Hu,^{*a*} Yaru Qin,^{*a*} Yahong Li, ^{**a*} Wu Li^{*c*} and Wei Liu ^{**a*}

A new imidazo[1,5-a]pyridine-containing pyrrolyl ligand HL (HL = 3-(1H-pyrrol-2-yl)imidazo[1,5-a]pyridine) has been synthesized and employed to the organometallic chemistry of titanium. The syntheses, structures, catalytic properties and antitumor activity of three titanium complexes supported by HL are reported. Reactions of Ti(NMe₂)₄ and Ti(NEt₂)₄, respectively, with 2 equivalents of HL, lead to the production of titanium bisamido complexes TiL₂(NMe₂)₂ (1) and TiL₂(NEt₂)₂ (2). Treatment of Ti(OⁱPr)₄ with 2 equivalents of HL results in the formation of TiL₂(OⁱPr)₂ (3). All complexes have been characterized by elemental analyses and NMR studies. The solid-state structures of 2 and 3 have been further established by single X-ray crystallography. The titanium bisamido complexes 1 and 2 are shown to be good pre-catalysts for the hydroamination of alkynes. Complex 1 was found to be active catalyst for the ring-opening polymerization of ε -caprolactone. The cytotoxicity activities of 3 towards the tumor cells HCT-116, PC3 and MCF-7 were measured. Complex 3 exhibited good antitumor properties.


Introduction


The organometallic chemistry of titanium has received growing attention from many groups around the world.¹ The efforts of these groups are driven by a number of impetuses, but the three most important factors are the development of precatalysts for alkyne and alkene hydroamination reactions,2 the employment of titanium complexes as the initiators for the polymerization of olefin³ and cyclic ester,⁴ and the investigation of cytotoxicity of titanium compounds towards cancer cells.⁵ Hydroamination is the addition of N-H bond across an unsaturated C-C bond. Since hydroamination of alkyne or alkene provides an important avenue for the efficient synthesis of imines, enamines and nitrogen-containing heterocycles with a 100% atom-economical fashion, hydroamination reaction has been the subject of ever-increasing scrutiny over the past two decades.² Numerous catalysts based on the elements stretched across the periodic table have been found to be able to catalyze this transformation.⁶ Among which the titanium complexes have been proved particularly useful.^{2a-c} The advantages of titanium catalysts over late transition metals are improved cost effectiveness and low toxicity. The titanium compounds are also preferred over rare-earth catalysts owing to their enhanced robustness and broad functional group scope.

The recent advances of titanium catalyzed hydroamination reveal that the regiochemical outcome of the reaction could be dramatically controlled by utilizing different ligands. Thus, a plethora of ancillary ligands, e.g., Cp-based molecules,⁷ pyrrolyl ligands,⁸ amidate compounds,⁹ imidazole-containing ligands¹⁰ and phenolate,¹¹ etc., are reported. However, employment of a multidentate ligand in which a pyrrolyl moiety and a N-containing heterocycle were incorporated in one molecule entity, has rarely been explored. Aiming at exploring the influences of the structure of the ligands on the regioselectivity of the hydroamination products and continuing our ongoing efforts on studying the hydroamination of alkynes catalyzed by titanium compounds supported by pyrrolyl ligands,^{8a-b} we expand our efforts to synthesize titanium pre-catalysts coordinated by 3-(1H-pyrrol-2-yl)imidazo[1,5-a]pyridine (HL, Scheme 1), which contains both a pyrrolyl ring and an imidazo[1,5a)pyridine moiety. The reactions of HL with $Ti(NMe_2)_4$, $Ti(NEt_2)_4$, and $Ti(O'Pr)_4$, respectively, gave complexes $TiL_2(NMe_2)_2$ (1), $TiL_2(NEt_2)_2$ (2) and $TiL_2(O'Pr)_2$ (3). Herein we report the syntheses and characterizations of these complexes. The catalytic activities of 1 and 2 towards the intermolecular hydroamination of alkynes, the ring-opening polymerization of ε -caprolactone initiated by 1, and the cytotoxicity activities of 3 towards the tumor cells HCT-116, PC3 and MCF-7 were also investigated.

Results and discussion Synthesis of the HL ligand

The ligand HL was prepared by the reaction of 1*H*-pyrrole-2carbonyl chloride and 2-pyridylmethanamine in the presence of T_3P (50 wt% in DMF). The ligand HL was obtained in good yield and ARTICLE






Scheme 1 Structure of the ligand.

Syntheses of the titanium complexes

Treatment of HL with THF solution of $Ti(NMe_2)_4$ and $Ti(NEt_2)_4$, respectively, led to the formations of $TiL_2(NMe_2)_2$ (1) and $TiL_2(NEt_2)_2$ (2) (Scheme 2). The reaction of $Ti(O^iPr)_4$ with 2 equiv. of HL afforded $TiL_2(O^iPr)_2$ (3) (Scheme 2). Complexes 1-3 were readily obtained in good yields. They were also characterized by ¹H and ¹³C NMR spectra and elemental analyses.

Crystals suitable for X-ray diffraction of **2** and **3** were grown from toluene solutions which were left standing at room temperature in a vibration-free environment for a week.



Scheme 2 Syntheses of $TiL_2(NMe_2)$ (1), $TiL_2(NEt_2)$ (2) and $TiL_2(OiPr)_2$ (3).

Structure descriptions of 2 and 3

The molecular structures of 2 and 3 in the solid state have been confirmed by X-ray analysis and are shown in Figs. 1, 2 and 3, respectively. The crystallographic data and experimental details for structural analyses are summarized in Table 1. Selected bond distances and angles are listed in Table 2.

The single crystal analysis revealed that **2** crystallizes in monoclinic crystal system of the P2₁/c space group and displays several interesting features. The overall structure of **2** includes two molecules (Fig. 1), and the two individual molecules are not completely symmetrical. The central Ti(IV) atom is six-coordinated by four nitrogen atoms from two bidentate L⁻ ligands and two amides in *cis* arrangement, displaying a distorted octahedral coordination environment. The bond lengths between titanium atom and donor imidazopyridine nitrogen atoms (Ti1-N1 = 2.236(3) Å, and Ti1-N4 = 2.277(3) Å) are apparently longer than those of the Ti - N(pyrrolyl) distances (Ti1-N2 = 2.148(3) Å, and Ti1-N4 = 2.123(3) Å). One donor imidazopyridine nitrogen atom of the ligand and one amide atom are in *trans* arrangement, with bond angles of 87.69(10)° (N2-Ti1-N3) and 97.53(11)° (N5-Ti1-N2), summing to185.22° (Fig. 2).




Fig. 1 ORTEP structural drawing of 2.




Fig. 2 Partially labeled structure of one of molecules of 2.




Fig. 3 ORTEP structural drawing of 3.

Table 1 Crystal data and str	ucture refinements f	01 2 alla 3	Table 2 Selected bo	Ū (
Complay	2	2	Ti(1)-N(1)	2.236(3)	Ti(1)-N(2)	2.148(3)	
Complex	2	3	Ti(1)-N(3)	2.277(2)	Ti(1)-N(4)	2.123(3)	
Empirical formula	C30H36N8Ti	C28H30N6O2Ti	Ti(1)-N(5)	1.912(3)	Ti(1)-N(6)	1.910(3)	
Empiricariormana	03011301 (811	02811301100211	N(1)-Ti(1)-N(3) N(4)-Ti(1)-N(3)	76.45(9) 74.90(10)	N(2)-Ti(1)-N(3) N(5)-Ti(1)-N(3)	87.69(10) 167.17(11	
Formula weight	556.54	530.45	N(4)-Ti(1)-N(3) N(6)-Ti(1)-N(3)	88.51(10)	N(2)-Ti(1)-N(1)	73.82(10)	
			N(4)-Ti(1)-N(1)	84.61(9)	N(2) - Ti(1) - N(1)	93.69(11)	
Temperature	296(2) K	293(2) K	N(6)-Ti(1)-N(1)	162.79(10)	N(4)-Ti(1)-N(2)	155.02(10	
Wavelength	0.71073 Å	0.71073 Å	N(5)-Ti(1)-N(2)	97.53(11)	N(6)-Ti(1)-N(2)	97.57(11)	
wavelength	0./10/3 A	0./10/3 A	N(5)-Ti(1)-N(4)	96.26(11)	N(6)-Ti(1)-N(4)	99.70(11)	
Crystal system	Monoclinic	Monoclinic	N(6)-Ti(1)-N(5)	102.32(12)			
Space group	$P2_1/c$	C 2/c	3 Ti(1)-O(1)	1.7799(13)	Ti(1)-N(1A)	2.2209(15	
Space Broup	1200	0 2/0	Ti(1)-O(1A)	1.7798(13)	Ti(1)-N(2)	2.1003(16	
	a = 23.010(9) Å	a = 8.7336(17) Å	Ti(1)-N(1)	2.2209(16)	Ti(1)-N(2A)	2.1004(16	
			O(1)-Ti(1)-N(1)	90.02(6)	O(1A)-Ti(1)-N(2A)	103.11(6)	
	b =13.712(5) Å	b =16.212(6) Å	O(1)-Ti(1)-N(1A)	167.20(6)	N(1A)-Ti(1)-N(1)	80.70(8)	
	21.229(0) \$	10.052(4)	O(1)-Ti(1)-N(2)	103.11(6)	N(2)-Ti(1)-N(1)	74.28(6)	
Unit cell dimensions	c = 21.228(9) Å	c = 18.952(4) Å	O(1)-Ti(1)-N(2A)	95.96(6)	N(2)-Ti(1)-N(1A)	82.96(6)	
Unit cen uniensions	$\alpha = 90^{\circ}$	$\alpha = 90^{\circ}$	O(1A)-Ti(1)-O(1) O(1A) Ti(1) N(1)	100.41(9) 167.20(6)	N(2A)-Ti(1)-N(1) N(2A)-Ti(1)-N(1A)	82.96(6)	
	<i>w</i> , , ,	u , , ,	O(1A)-Ti(1)-N(1) O(1A)-Ti(1)-N(1A)	74.28(6) 150.07(9)			
	β=115.456(7)°	β=92.30(3) °		90.02(6)	N(2A)-Ti(1)-N(2)	150.07(5)	
			O(1A)-Ti(1)-N(2)	95.96(6)			
	$\gamma = 90^{\circ}$	$\gamma = 90^{\circ}$	The single cryst	al X-ray diffr	action determination	indicates th	
Volume	6048(4) Å ³	2681.2(13) Å ³	the octahedral Ti(IV	V) ion of 3 is	surrounded by four n to L^2 ligands and two	trogen ator	
Z	8	4	(O1 and O1A) from	n isopropoxic	le groups. The N1, C	1, N1A, a	
$\rho(mg \cdot m^{-3})$	1.222	1.314	O1A atoms are equatorial coplanar, with the bond angles of 90.06(6)°, 100.41(9)°, 90.02(6)° and 80.70(8)°, respectively, summing to 361.19°, with the deviation being 1.19° compared with				
F(000)	2352	1112			veen titanium atom		
Crystal size(mm ³)	0.60 x 0.40 x 0.40	0.60 x 0.40 x 0.40	imidazopyridine nitrogen atoms (Ti1-N1 = $2.2209(16)$ Å, and T N1A = $2.2209(15)$ Å) are apparently longer than those of the T N(pyrrolyl) distances (Ti1-N2 = $2.1003(16)$ Å, and Ti1-N2A				
θ range/°	1.78° to 26.22	3.31° to 27.49°	N(pyrrolyl) distance 2.1004(16) Å).	es (111-N2 =	= 2.1003(16) A, and	111-N2A	
	$-28 \le h \le 23$	$-9 \le h \le 11$	Hydroamination o	f alkynes cata	alyzed by 1 and 2		
Limiting indices	$-25 \le 1 \le 26$	$-20 \le k \le 20$			es of 1 and 2, we inv		
Limiting indices	-25 ≤1 ≤ 20	$-20 \le K \le 20$			ion of alkynes (diphe	5 5	
	$\text{-16} \le k \le 17$	$-24 \le l \le 24$			tylene, 1-hexyne, ar The results are show		
Reflections collected/ unique	35810 / 12166	12023 / 3070			oth 1 and 2 could		
Data / restraints / parameters	12094 / 0 / 711	3048 / 0 / 170	The Markovnikov p	product is favo	1-octyne (entries 4, ored product of hydroa rmined for symmetric	mination. 1	
GOF	0.950	1.076	To further probe	the scope of	the catalysis, a large	selection	
	D 0.0505				ns with 1-octyne. The Markovnikov produ		
D1 = D2[1 > 2-(1)]	$R_1 = 0.0507$	$R_1 = 0.0456$			most arylamines hydr		
R1,wR2[I> $2\sigma(I)$]	$wR_2 = 0.11111$	$wR_2 = 0.1289$	octyne in >60% y	eld and with	high regioselectivitie	s. This is	
		-			is the precatalyst, ¹² v		
	$R_1 = 0.1290$	$R_1 = 0.0578$			Idition, most of substi		
R1,wR2(all data)	mD = 0.1429	mD = 0.1265			en 2-chloroaniline was with high regioselec		
	$wR_2 = 0.1438$	$wR_2 = 0.1365$			6). 2-Methoxy-phenyl		
Largest diff. peak and					with lower regioselect		
J 1	0.276 and -0.249	0.369 and -0.271			I, the yields of hydro		
hole(e•Å ³)					than that of 1. This is		

to the slightly larger steric impediment of the diethyl amide group. The yields of the hydroamination reactions by 1 or 2 are higher than

that of Ti(imidazol-2-yl)(NMe₂)₃.¹⁰

ARTICLE


$R_{1} = R_{2} + 1.5 \text{ Br} - NH_{2} \xrightarrow{1100 \text{ mol% catalyst,}} 212 \text{ catalyst,} Br - NH_{2} + HN_{2} \xrightarrow{Br} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}$									
(R ₁ , R ₂)=(Ph, F (n-Pr, (n-Bu	n-Pr); (Ph, H)	60 °C	For R ₂ =H Markovni (M)		∠ ∕Iarkovnikov (AM)				
Entry	Catalyst	Alkyne	Product	M/ant i-M ^b	Yield $(\%)^a$				
1	1	Ph-=-Ph							
2		Et——Et							
3		n-Pr————————————————————————————————————							
4		n-Bu-==	Br	88:12	38				
5		n-Hex—	Br	98:2	73				
6	2	Ph-=Ph							
7		EtEt							
8		n-Pr							
9		n-Bu—	Br	92:8	47				
10		n-Hex—	Br	97:3	91				

^{*a*} Isolated yields after reduction by LiAlH₄. ^{*b*} By GC-MS analysis.

 Table 4 Hydroamination of 1-octyne with amines catalyzed by 1 and

 2

n-Hex \longrightarrow + 1.5 Ar $-NH_2$ $\xrightarrow{1)10 \text{ mol% catalyst,}}_{2ML \text{ Tol, } 120^{\circ}\text{C}}$ $Ar - NH_2$ $\xrightarrow{2ML \text{ Tol, } 120^{\circ}\text{C}}_{60^{\circ}\text{C}}$ $Ar - NH_2$ $Ar - NH_$									
Entry	Amine	Product	Cat.	M/anti-M	Yield (%)				
1	NH2	~ ^{ll}	1	92:8	73				
2	Br	Br	2	97:8	91				
3	NH ₂	, H	1	97:3	70				
4	a	a	2	95:5	77				
5	NH2	→ ^H N	1	94:6	22				
6	K Cl		2	91:9	21				
7	NH ₂	CI CI	1	96:4	65				
8	a <u>d</u>		2	94:4	79				
9	NH ₂	, → ^H	1	99:1	93				
10	CI	a	2	87:13	85				
11	NH2		1	92:8	52				
12	F	F	2	100:0	79				
13	NH ₂	, ^H	1	94:6	72				
14	F	∥F ∣	2	96:4	59				
15	NH ₂		1	92:8	68				
16			2	89:11	86				
17	NH ₂		1	75:25	62				
18		, second	2	62:38	77				



^{*a*} Isolated yields after reduction by LiAlH₄. ^{*b*} By GC-MS analysis.

Ring-opening polymerization of ε-caprolactone initiated by complex 1

Metal-catalyzed ring-opening polymerization (ROP) of lactones is one of the most promising processes for the preparation of environmentally friendly and biomedical polyesters, and it provides an alternative in the synthesis of well-characterized biodegradable polymers. While rare earth metal complexes were well known to efficiently catalyze the polymerization of lactones because of the highly electropositive nature of the lanthanides,¹³ the titanium(IV) complexes have also been found to initiate the polymerization of ε caprolactone over the past few years.¹⁴ The titanium compounds chelated by alkoxide or aryloxide ligands have long been recognized to have significant applications in polymerization catalysis,¹⁵ but the potential of titanium complexes supported by imidazopyridinecontaining pyrrolyl ligands, has never been explored. Thus, we investigated the catalytic behavior of complexes **1**, **2** and **3** towards ring-opening polymerization of ε -caprolactone.

The initial studies were performed using $TiL_2(O'Pr)_2$ (3) as the initiator. It was found that 3 showed low activity for the polymerization. The polymerization reaction proceeded very slowly and low yields of polymers were generated after 24 h at 60°C (Table S4, Supporting Information). Next, the polymerization recation was conducted by employing 1 as the initiator, and utilizing dimethyl ether (DME), tetrahydrofuran (THF), and toluene, respectively, as the solvents at 60°C and 80°C. To our delight, complex 1 can effectively initiate ε-caprolactone polymerization, and the obtained polymers have high molecular weights and relatively narrow molecular weight distributions (PDIs). The polymerization results are summarized in Table 5. The solvents have the obvious effect on the yields of the polymers. When the polymerization was conducted in THF, poor or moderate yields were afforded (68% and 60% in THF). However, no observable polymerization initiated by complex 2 occurred at 80°C after 24 h.

Cytotoxicity

Recently, titanium (IV) complexes have been studied as antitumor compounds with the expectation for substituting for platinum compounds.¹⁷ The 'salan' isopropoxide titanium(IV) complexes, which are based on tetradentate diaminobis(phenolato) ligands were demonstrated high antitumor activity;¹⁸ whereas the cytotoxicity of the 'pyrrolyl' isopropoxide titanium(IV) complexes was rarely studied.¹⁹ In order to investigate the influences of the ligand structures on the properties of the Ti(IV) complexes, we studied the anticancer features of complex **3**.

The cytotoxic activity of **3** was studied on HCT-116, PC3 and MCF-7 cells, employing the methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay. Relative IC_{50} and maximal inhibition values are listed in Table 6. Cytotoxicity plots are given in Fig. 4.

It is evident that **3** exhibits variable cytotoxicity. Compared with cisplatin,²⁰ complex **3** shows an obvious cytotoxic effect towards HCT-116, PC3 and MCF-7 cells, with the IC₅₀ values of 21.87, 31.37 and 14.17 μ M, respectively. These IC₅₀ data are close to or better than cisplatin (3.79, 33.3, and 46.9 μ M towards HCT-116, PC3 and MCF-7 cells, respectively).

Initiator

Entry

Table 5 Polymerization of ϵ -caprolactone initiated by	1
---	---

[M]/[I]

t/h

solvent


tiated by 1						
Yield/% ^a	T/°C	$Mn(calc)^{b}(10^{4})$	$Mn^{c}(10^{4})$	$Mn(obsd)^{d}(10^{4})$	PDI	Efficiency/%
82	80	1.87	267	1.40	1 20	70.0

•							, , ,		, , , ,		
1	1	DME	200	5	82	80	1.87	2.67	1.49	1.39	70.0
2	1	DME	200	10	79	60	1.80	2.33	1.30	1.50	77.2
3	1	THF	200	12	68	80	1.55	2.48	1.39	1.49	53.4
4	1	THF	200	17	60	60	1.36	1.94	1.09	1.39	70.4
5	1	Tol	200	3	89	80	2.03	3.30	1.85	1.22	61.5
6	1	Tol	200	4	86	60	1.96	2.25	1.26	1.47	87.0

^{*a*}Yield: weight of polymer obtained/weight of monomer used. ^{*b*}Mn(calc) = $M_{mono} * [M] / [I] * Conv.$ ^{*c*}Measured by GPC relative to polystyrene standards. ^dMeasured by GPC relative to standards with Mark-Houwink corrections¹⁶ for Mn (obsd) = 0.56 Mn (GPC) for ε -caprolactone.

Table 6 Relative IC₅₀ and maximal inhibition values for 3

		IC ₅₀		maximal inhibition ^a (%)			
Compound	HCT-116	PC3	MCF-7	HCT-116	PC3	MCF-7	
$Ti~(O^iPr)_2L_2({\bf 3})$	21.87	31.37	14.17	89	81	83	






Fig. 4 Cell survivals in response to complex 3 towards cell HCT-116, PC-3. MCF-7.

Conclusions

In summary, three complexes $TiL_2(NMe_2)_2(1)$, $TiL_2(NEt_2)_2(2)$, and $TiL_2(O^{1}Pr)_2$ (3) were synthesized and characterized. The catalytic behaviors of these complexes towards the hydroamination of alkynes, ring-opening polymerization of εcaprolactone and their cytotoxicity were investigated. Complexes 1 and 2 were able to catalyze the hydroamination of alkynes, and showed higher catalytic activity and gave highly Markovnikov selective hydroamination of 1-octyne. Complex 1 also exhibited good catalytic activity for ring-opening polymerization of *ɛ*-caprolactone. High cytotoxicities were obtained for **3**, indicating that pyrrolyl–titanium(IV) complexes may serve as a new family of antitumor agents towards HCT-116, PC3 and MCF-7 cells.

Experimental section General considerations

All manipulations of air-sensitive compounds were carried out in an MBraun glovebox in a purified nitrogen atmosphere. Anhydrous THF, DME and toluene were freshly distilled from purple sodium benzophenone ketyl for at least 4 days. ¹H and ¹³C spectra were recorded on Innova-400 spectrometers at ambient temperature using TMS as an internal standard, and chemical shifts of carbon, hydrogen and nitrogen atoms were performed with a Carlo - Erba EA1110 CHNOS microanalyzer.

X-ray crystallography

Crystals grown from concentrated solutions at room temperature were quickly selected and mounted on a glass fiber in wax. The data collections were carried out with a Mercury CCD detector equipped with graphite-monochromated Mo-Ka radiation by using the φ/ω scan technique at room temperature. The structures were solved by direct methods with SHELXS-97.21 The hydrogen atoms were assigned with common isotropic displacement factors and included in the final refinement by use of geometrical restraints. A full-matrix leastsquares refinement on F^2 was carried out using SHELXL-97.

General procedure for hydroamination reactions

To a 30 mL pressure tube was added the pre-catalyst (0.1 mmol), amine (1.5 mmol), alkyne (1 mmol) and toluene (5 mL) in a drybox. The pressure tube was sealed with a Teflon screw cap, taken out of the drybox and heated at 120°C for 24 h. Then at 0°C the reaction solution was carefully added to a suspension of LiAlH₄ in toluene and the mixture was refluxed for 12 h at 60°C. After cooling the solution to 0°C, the excess LiAlH₄ was hydrolyzed with sodium sulphate decahydrate. The mixture was filtered to remove sodium sulphate decahydrate. The solvent was concentrated under vacuum. Column chromatography of the residue on silica gel afforded the pure amine derivatives.

Typical polymerization procedure

A THF solution of complex 1 (0.0250 g, 0.05 mmol) and ε caprolactone (1.14 g, 10 mmol) was added to a 30 mL pressure tube equipped with a magnetic stirring bar in a glovebox. Afterwards, the pressure tube was taken out from the glovebox. The reaction mixture was heated to 80°C for 12 h and then terminated by addition of a mixture of conc. HCl/EtOH (1:5 V/V) (2 mL). Petroleum ether (20 mL) was added to give yellow solids. The solids were dissolved in THF (20 mL), column chromatography on Al₂O₃ to give a white solid. Yield: 0.78 g (68 %).

General considerations for cytotoxicity

Cytotoxicity was measured on colorectal cancer cell HCT-116, adenocarcinoma MCF-7 and PC-3 using the methylthiazolyldiphenyl tetrazolium bromide (MTT) assay. HCT 116 cells were cultured at 37°C in a 5% CO₂ atmosphere incubator in modified McCoy's 5A medium (sigma) complemented with 10% fetal bovine serum (FBS, Hyclone) containing 1% penicillin and 1% streptomycin (Sigma). MCF-7 was maintained in RPMI 1640 medium with 10% FBS and PC3 in F-12K medium with 10% FBS. For cytotoxicity assay, HCT 116, MCF-7 and PC-3 cells were seeded into 96-well plates at densities of 5000 cells per well and maintained for 24 h. Next, the cells were incubated with the reagents tested at different concentrations for another 72 h in modified McCoy's 5A medium containing 10% FCS. After that, MTT (5 mg/mL in 20 µL) was added and the cells were incubated for additional 4 h. The supernatant was removed, and the precipitates were dissolved in 150 mL of DMSO. The absorbance at 490 nm was measured. Relative IC₅₀ values with standard error of means were determined by a nonlinear regression of a variable slope model.

Synthesis of the ligand and complexes 1-3

3-(1H-pyrrol-2-yl)imidazo [1,5-a]pyridine (HL). To a stirred solution of 1H-pyrrole-2-carbonyl chloride (10 mmol) in CH₂Cl₂ was added pyridine (2 mL) followed by substituted 2pyridylmethanamine (10 mmol) at room temperature. The reaction mixture was stirred for 1 h and added 30 mL water. The reaction was neutralized by NaHCO₃ and extracted with ethylacetate; then the organic layer was dried and concentrated to give the amide (N-(pyridin-2-ylmethyl)-1*H*-pyrrole-2-carboxamide). To the amide added 9 mL of T₃P (50 wt% in DMF) and refluxed for 3 h at 125°C. This was poured into cold water and neutralized with ammonia solution. The water layer was extracted three times with ethylacetate. The combined organic phases were dried over anhydrous Na₂SO₄ and evaporated under vacuum. The residue, thus obtained was purified by column chromatography using ethylacetate and hexane as solvent system to get the product. ¹H NMR (400 MHz, CDCl₃) δ 12.14 (s, 1H), 8.39 - 8.28 (m, 1H), 7.51 (s, 1H), 7.45 (d, 1H), 7.02 (d, 1H), 6.76 - 6.58 (m, 3H), 6.41 (dd, 1H); ¹³C NMR (101 MHz, CDCl₃) & 133.32, 130.71, 122.01, 119.86, 119.21, 118.72, 118.33, 113.31, 109.16, 106.07. Anal. Calc. for HL: C 72.11; H 4.95; N 22.94%. Found: C 71.79; H 5.06; N 22.61%.

TiL₂(**NMe**₂)₂ (1). To a solution of Ti(NMe₂)₄ (0.112 g, 0.5 mmol) in THF (2 mL) was added dropwise HL (0.1830 g, 1 mmol) in THF (5 mL). After stirring at room temperature for 24 h, the volatiles were removed under reduced pressure to give a red solid. Yield: 0.47 g (93%). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, 2H, C₇H₅N₂), 7.54 (s, 2H, C₇H₅N₂), 7.06 (d, 2H, C₇H₅N₂), 6.62 (d, 2H, pyrrole-H), 6.53 – 6.39 (m, 6H, C₇H₅N₂ + pyrrole-H), 6.28 (s, 2H, pyrrole-H), 3.35 (s, 12H, CH₃). ¹³C NMR (100 MHz, CDCl₃) δ 138.41, 130.93, 129.01, 128.70, 122.06, 119.09, 117.65, 115.87, 113.31, 108.90, 103.68, 68.17, 47.37. Anal. Calc. for C₂₆H₂₈N₈Ti: C 62.40; H 5.64; N 22.39%. Found: C 62.32; H 5.82; N 22.43%.

TiL₂(NEt₂)₂ (2). The synthesis of complex 2 was carried out in the same way as that described for complex 1, but Ti(NEt₂)₄ (0.186 g, 0.5 mmol) was used instead of Ti(NMe₂)₄. The volatiles were removed under reduced pressure to give a red-brown solid. Yield: 0.50 g (89%). Red crystals were obtained in toluene. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, 2H, C₇H₅N₂), 7.61 (s, 2H, C₇H₅N₂), 7.06 (d, 2H, C₇H₅N₂), 6.62 (d, 2H, pyrrole-H), 6.47 (dd, 8H, C₇H₅N₂ + pyrrole-H), 4.22 – 3.74 (m, 8H, CH₂), 0.62 (t, 12H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 137.92, 131.65, 128.84, 128.25, 121.99, 118.92, 117.44, 115.76, 113.05, 108.71, 103.24, 45.21, 12.82. Anal. Calc. for C₃₀H₃₆N₈Ti: C 64.74; H 6.52; N 20.13%. Found: C 64.83;

H 6.57; N 19.71%.

Ti(OⁱPr)₂L₂ (3). To a solution of Ti(OⁱPr)₄ (0.1421 g, 0.5 mmol) in tetrahydrofuran (2 mL), HL (0.1830 g, 1.0 mmol) in tetrahydrofuran was added at room temperature. After stirring at room temperature for at least 24 h, THF was evaporated completely under reduced pressure to give an orange solid. The product was obtained as light orange block crystals after crystallized from toluene. Yield: 80% (0.4135 g). ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, 2H, C₇H₅N₂), 7.51 (d, 2H, C₇H₅N₂), 7.15 – 7.00 (m, 2H, C₇H₅N₂), 6.59 (d, 2H, pyrrole-H), 6.52 – 6.38 (m, 6H, C₇H₅N₂ + pyrrole-H), 6.20 (s, 2H, pyrrole-H), 4.79 – 4.58 (m, 2H, CH), 1.17 (d, 6H, CH₃), 1.00 (d, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 138.63, 132.05, 128.74, 128.21, 121.92, 119.15, 117.76, 115.90, 113.49, 108.42, 103.41, 79.19, 25.55. Anal. Calc. for C₂₈H₃₀N₆O₂Ti: C 63.40; H 6.70; N 15.84%. Found: C 63.73; H 5.60; N 16.23%.

Acknowledgements

We thank Professor Zhijun Zhang of Suzhou Institute of Nanotech and Nano-bionics for assistance with cytotoxicity measurement. The authors appreciate the financial supports of Natural Science Foundation of China (21272167 and 21201127), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, and KLSLRC (KLSLRC-KF-13-HX-1).

Notes and references

^a College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215006, China. E-mail: liyahong@suda.edu.cn; weiliu@suda.edu.cn.

^b Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, Suzhou 215125, China.

^c CAS Key Laboratory of Salt Lake Resources and Chemistry, Qinghai Institute of Salt Lakes, Chinese Academy of Sciences, Xining 810008, China

[†] Electronic Supplementary Information (ESI) available:Crystallography, ¹H and ¹³C NMR data. CCDC reference numbers 1030010 and 990411 for complex **2** and **3**, respectively. For ESI and crystallographic data in CIF or other electronic see DOI: 10.1039/b000000x/

- For selected examples, see: (a) N. Hazari and P. Mountford, Acc Chem. Res., 2005, 38, 839-849; (b) A. D. Schwarz, A. J. Nielson, N. Kaltsoyannis and P. Mountford, Chem. Sci., 2012, 3, 819–824; (c) Y. H. Li, Y. H. Shi and A. L. Odom, J. Am. Chem. Soc., 2004, 126, 1794-1803; (d) I. Prochnow, P. Zark, T. Müller and S. Doye, Angew. Chem., Int. Ed., 2011, 50, 1 – 6; (e) L. H. Gade, Acc. Chem. Res., 2002, 35, 575-582; (f) S. W. Hu, T. Shima and Z. M. Hou, Nature, 2014, 512, 413-415; (g) T. Shima, S. W. Hu, G. Luo, X. H. Kang, Y. Luo and Z. M. Hou, Science, 2013, 340, 1549-1552; (h) H. Shen and Z. W. Xie, J. Am. Chem. Soc., 2010, 132, 11473-11480; (i) V. N. Cavaliere, M. G. Crestani, B. Pinter, M. Pink, C. Chen, M. Baik and D. J. Mindiola, J. Am. Chem. Soc., 2011, 133, 10700–10703; (j) R. Thompson, C. Chen, M. Pink, G. Wu and D. J. Mindiola, J. Am. Chem. Soc., 2014, 136, 8197–8200.
- 2 For selected reviews and recent papers, see: (a) T. E. Müller, K. C. Hultzsch, M. Yus, F. Foubelo and M. Tada, *Chem. Rev.*, 2008, **108**, 3795; (b) A. L. Odom, *Dalton Trans.*, 2005, 225-233; (c) G. F. Zi, *J. Organomet. Chem.*, 2011, **696**, 68-75; (d) R. Severin, S. Doye, *Chem. Soc. Rev.*, 2007, **36**, 1407-1420; (e) H. Shigehisa, N. Koseki, N. Shimizu, M. Fujisawa, M. Niitsu and K. Hiroya, *J. Am. Chem. Soc.*,

2014, 136, 13534-13537; (f) A. J. Musacchio, L. Q. Nguyen, G. H.
Beard and R. R. Knowles, J. Am. Chem. Soc., 2014, 136, 12217-12220; (g) A. R. Ickes, S. C. Ensign, A. K. Gupta and K. L. Hull, J. Am. Chem. Soc., 2014, 136, 11256-11259. (h) A. Zhdanko and M. E.
Maier, Angew. Chem. Int. Ed., 2014, 53, 7760-7764; (i) T. M.
Nguyen, N. Manohar and D. A. Nicewicz, Angew. Chem. Int. Ed., 2014, 53, 6198-6201; (j) M. J. Goldfogel, C. C. Roberts and S. J.
Meek, J. Am. Chem. Soc., 2014, 136, 6227-6230.

- 3 (a) F. Gornshtein, M. Kapon, M. Botoshansky and M. S. Eisen, Organometallics, 2007, 26, 497-507; (b) I. Saeed, S. Katao and K. Nomura, Organometallics, 2009, 28, 111-122; (c) K. H. Tam, M. C. W. Chan, H. Kaneyoshi, H. Makio and N. Zhu, Organometallics, 2009, 28, 5877-5882; (d) W. H. Sun, S. Liu, W. Zhang, D. Wang and T. Liang, Organometallics, 2010, 24, 732-741; (e) M. Delferro and T. J. Marks, Chem. Rev., 2011, 111, 2450-2485; (f) L. Wang, Q. Wu, H. Xu and Y. Mu, Dalton Trans., 2012, 41, 7350-7357; (g) X. C. Shi and G. X. Jin, Organometallics, 2012, 31, 7198-7205; (h) S. Liu, A. Motta, M. Delferro and T. J. Marks, J. Am. Chem. Soc., 2013, 135, 8830-8833; (i) S. Liu, A. Motta, A. R. Mouat, M. Delferro and T. J. Marks, J. Am. Chem. Soc., 2014, 136, 10460-10469; (j) J. G. M. Morton, H. Al-Shammari, Y. Sun, J. Zhu and D. W. Stephan, Dalton Trans., 2014, 43, 13219-13231.
- (a) R. R. Gowda, D. Chakraborty and V. Ramkumar, *Inorg. Chem. Commun.*, 2011, 14, 1777–1782; (b) E. L. Whitelaw, M. D. Jones, M. F. Mahon and G. Kociok-Kohn, *Dalton Trans.*, 2009, 9020–9025; (c) D. Deivasagayam and F. Peruch, *Polymer*, 2011, 52, 4686-4693; (d) C. Y. Li, C. J. Yu and B. T. Ko, *Organometallics*, 2013, 32, 172–180; (e) R. L. Webster, *RSC Adv.*, 2014, 4, 5254–5260; (f) C. Y. Tsai, H. C. Du, J. C. Chang, B. H. Huang, B. T. Ko and C. C. Lin, *RSC Adv.*, 2014, 4, 14527–14537.
- 5 (a) R. Hernandez, J. Mendez, J. Lamboy, M. Torres, F. R. Roman and E. Melendez, *Toxicol. in Vitro*, 2010, 24, 178–183; (b) S. Gómez-Ruiz, B. Gallego, Ž. Žižak, E. Hey-Hawkins, Z. D. Juranić and G. N. Kaluđerović, *Polyhedron*, 2010, 29, 354–360; (c) L. M. Gao, J. Matta, A. L. Rheingold and E. Meléndez, *J. Organomet. Chem.*, 2009, 694, 4134–4139.
- 6 (a) S. D. Lee, J. C. Timmerman and R. A. Widenhoefer, Adv. Synth. Catal., 2014, 356, 3187-3192; (b) A. G. M. Barrett, C. Brinkmann, M. R. Crimmin, M. S. Hill, P. Hunt and P. A. Procopiou, J. Am. Chem. Soc., 2009, 131, 12906-12907; (c) M. A. Savolainen, X. P. Han and J. Wu, Org. Lett., 2014, 16, 4349-4351; (d) M. R. Crimmin, M. Arrowsmith, A. G. M. Barrett, I. J. Casely, M. S. Hill and P. A. Procopiou, J. Am. Chem. Soc., 2009, 131, 9670-9685; (d) Z. Chai, D. Z. Hua, K. Li, S. L. Zhou, J. Chu and G. S. Yang, J. Organomet. Chem., 2014, 768, 136-139; (e) A. Mukherjee, S. Nembenna, T. K. Sen, S. P. Sarish, P. K. Ghorai, H. Ott, D. Stalke and H. W. Roesky, Angew. Chem., Int. Ed., 2011, 50, 3968-3972; (f) J. F. Dunne, D. B. Fulton, A. Ellern and A. D. Sadow, J. Am. Chem. Soc., 2010, 132, 17680-17683; (g) M. R. Maurya, A. Arya, U. Kumar, A. Kumar, F. Avecilla and J. C. Pessoa, Dalton Trans., 2009, 9555-9566; (h) K. D. Hesp, S. Tobisch and M. Stradiotto, J. Am. Chem. Soc., 2010, 132, 413; (i) K. D. Hesp and M. Stradiotto, J. Am. Chem. Soc., 2010, 132, 18026-18029; (j) S. R. Mothe, M. L. Novianti, B. J. Ayers and P. W. H. Chan, Org. Lett., 2014, 16, 4110-4113; (k) Z. Liu, H. Yamamichi, S. T. Madrahimov and J. F. Hartwig, J. Am. Chem. Soc., 2011, 133, 2772-2782; (1) I. Nakamura, T. Onuma, R. Kanazawa, Y. Nishigai

Page 8 of 9

and M. Terada, Org. Lett., 2014, 16, 4198-4200; (m) N. Sakai, N. Takahashi and Y. Ogiwara, Eur. J. Org. Chem., 2014, 2014, 5078-5082; (n) C. B. Huehls, A. J. Lin and J. Yang, Org. Lett., 2014, 16, 3620-3623; (o) M. J. Gainer, N. R. Bennett, Y. Takahashi and R. E. Looper, Angew. Chem., Int. Ed., 2011, 50, 684-687; (p) S. Germain, Ε. Schulz and J. Hannedouche, ChemCatChem, 2014, 6, 2065-2073; (q) G. Zi, Dalton Trans., 2009, 9101-9109; (r) J. C. Bernhammer, N. X. Chong, R. Jothibasu, B. B. Zhou and H. V. Huynh, Organometallics, 2014, 33, 3607-3617. (s) A. L. Reznichenko, H. N. Nguyen and K. C. Hultzsch, Angew. Chem., Int. Ed., 2010, 49, 8984-8987; (t) M. Zille, A. Stolle, A. Wild and U. S. Schubert, RSC Advances, 2014, 4, 13126-13133; (u) S. B. Amin and T. J. Marks, J. Am. Chem. Soc., 2007, 129, 10102-10103; (v) E. Kumaran, W. Y. Fan and W. K. Leong, Org. Lett., 2014, 16, 1342-1345; (w) T. Andrea and M. S. Eisen, Chem. Soc. Rev., 2008, 37, 550-567; (x) B. D. Stubbert and T. J. Marks, J. Am. Chem. Soc., 2007, 129, 4253-4271.

- 7 (a) R. Kubiak, I. Prochnow and S. Doye, *Angew. Chem., Int. Ed.*, 2010, 49, 2626-2629; (b) E. Haak, I. Bytschkov and S. Doye, *Angew. Chem., Int. Ed.*, 1999, 38, 3389-3391.
- 8 (a) F. Y. Zhou, M. S. Lin, L. Li, X. Q. Zhang, Z. Chen, Y. H. Li, Y. Zhao, J. Wu, G. M. Qian and B. Hu and W. Li, Organometallics, 2011, 30, 1283-1286; (b) Z. Chen, L. Li, Y. M. Chen, B. Hu, J. Wu, X. F. Wang and T. Lei, Y. H. Li, J. Chem. Res., 2012, 36, 249-253; (c) D. L. Swartz, R. J. Staples and A. L. Odom, Dalton Trans., 2011, 40, 7762-7768; (d) S. Majumder and A. L. Odom, Organometallics, 2008, 27, 1174-1177; (e) D. L. Swartz and A. L. Odom, Organometallics, 2007, 26, 6684-6684.
- 9 J. C. H. Yim, J. A. Bexrud, R. O. Ayinla, D. C. Leitch and L. L. Schafer, *J. Org. Chem.*, 2014, **79**, 2015-2028; (*b*) P. R. Payne, R. K. Thomson, D. M. Medeiros, G. Wan and L. L. Schafer, *Dalton Trans.*, 2013, **42**, 15670-15677.
- 10 Y. Zhao, M. S. Lin, Z. Chen, H. Pei, Y. H. Li, Y. M. Chen, X. F. Wang, L. Li, Y. Y. Cao, Y. Zhang and W. Li, *RSC Adv.*, 2012, 2, 144-150.
- 11 (a) I. A. Tonks, J. C. Meier and J. E. Bercaw, Organometallics, 2013, 32, 3451-3457; (b) B. Lian, T. P. Spaniol, P. Horrillo-Martinez and K. C. Hultzsch, J. Okuda, Eur. J. Inorg. Chem., 2009, 429-434.
- (a) P. L. McGrane and T. Livinghouse, J. Am. Chem. Soc., 1993, 115, 11485-11589; (b) E. Haak, I. Bytschkov and S. Doye, Angew. Chem., Int. Ed., 1999, 38, 3389-3391.
- (a) Y. M. Yao, X. P. Xu, B. Liu, Y. Zhang, Q. Shen and W. T. Wong, *Inorg. Chem.*, 2005, 44, 5133-5140; (b) Y. M. Yao, M. T. Ma, X. P. Xu, B. Liu, Y. Zhang, Q. Shen and W. T. Wong, *Organometallics*, 2005, 24, 4014-4020; (c) T. J. Woodman, M. Schormann, D. L. Hughes and M. Bochmann, *Organometallics*, 2004, 23, 2972-2979.
- 14 (a) H. Wang, H. Chan, J. Okuda and Z. Xie, *Organometallics*, 2005,
 24, 3118-3124; (b) X. Wang, A. Thevenon, J. L. Brosmer, I. Yu, S. I. Khan, P. Mehrkhodavandi and P. L. Diaconescu, *J. Am. Chem. Soc.*, 2014, 136, 11264–11267.
- (a) C. Li, C. Yu and B. T. Ko, *Organometallics*, 2013, **32**, 172-180;
 (b)M. G. Davidson, M. D. Jones, M. D. Lunn and M. F. Mahon, *Inorg. Chem.*, 2006, **45**, 2282-2287.
- 16 A. Kowalski, A. Duda and S. Penczek, *Macromolecules*, 1998, **31**, 2114-2122.

ARTICLE

- 17 K. M. Buettner and A. M. Valentine, *Chem. Rev.*, 2012, **112**, 1863-1881.
- (a) C. M. Manna, O. Braitbard, E. Weiss, J. Hochman and E. Y. Tshuva, *Chem. Med. Chem.*, 2012, 7, 703-708; (b) S. Meker, C. M. Manna, D. Peri and E. Y. Tshuva, *Dalton Trans.*, 2011, 40, 9802-9809; (c) M. Shavit, D. Peri, C. M. Manna, J. S. Alexander and E. Y. Tshuva, *J. Am. Chem. Soc.*, 2007, 129, 12098-12099; (d) D. Peri, S. Meker, C. M. Manna and E. Y. Tshuva, *Inorg. Chem.*, 2011, 50, 1030-1038; (e) D. Peri, S. Meker, M. Shavit and E. Y. Tshuva, *Chem. -Eur. J.*, 2009, 15, 2403-2415; (f) E. Y. Tshuva and D. Peri, *Coord. Chem. Rev.*, 2009, 253, 2098-2115; (g) C. M. Manna, G. Armony and E. Y. Tshuva, *Chem.-Eur. J.*, 2011, 17, 14094-14103; (i) S. Meker, K. Margulis-Goshen, E. Weiss, S. Magdassi and E. Y. Tshuva, *Angew. Chem.*, 2012, 124, 10667 10669.
- 19 M. Lin, Y. Cao, H. Pei, Y. Chen, J. Wu, Y. Li and W. Liu, *RSC Adv.*, 2014, 4, 9255-9260.
- 20 G. Kelter, N. J. Sweeney, K. Strohfeldt, H. Fiebig and M. Tacke, *Anticancer Drugs*, 2005, **16**, 1091-1098.
- 21 G. M. Sheldrick, SHELXS-97, *Program for solution of crystalstructures*, University of Göttingen, Germany, 1997.